CrossCoat Medical LLC Announces Horse Study Results That Could Help Millions Get a Better Night’s Sleep

LEXINGTON, Ky.–(BUSINESS WIRE)–CrossCoat Medical LLC (CCM) is pleased to announce the proposed medical
device (CCM-D) for treating snoring and obstructive sleep apnea (OSA)
has shown positive results in a recent pilot in vivo (equine) large
animal study.

“Our proposed medical device (CCM-D) involves injections of a protein
crosslinker to reduce palatal vibrations and airway blockages due to
excessive tissue compliance or floppiness. The matrix crosslinking bonds
are formed rapidly offering an almost immediate treatment effect,” says
Dr. Tom Hedman, CSO of CrossCoat Medical and a leading researcher in
soft-tissue biomechanics.

“Our National Institutes of Health funded study was successful in
demonstrating the potential effectiveness of genipin crosslink
augmentation in a pilot study with a living animal model – horses with
an exercise-induced palatal obstruction and snoring disorder (DDSP). The
single dose level that was evaluated in the pilot study demonstrated
varying levels of effectiveness in the DDSP horses with all of the
horses showing a reduction of snoring volume and two of the three horses
apparently fully “cured” by the treatment. The overall goal of these
studies is to provide information and data for an inexpensive,
immediately effective, safe and lasting means to eliminate severe
snoring and obstructive sleep apnea in humans.” Visit CrossCoatMedical.com
to hear actual audio recordings of a horse while exercising, pre- and
post-treatment, documenting the snoring loudness, palate displacement,
and gaps in breathing.

According to Dr. Tom Hedman, “The technology being developed by CCM is
effective within hours after application. Through the addition of
numerous, permanent, chemical bonds, the device significantly stabilizes
the tissue, reducing floppiness and increasing durability for immediate
and long-term treatment of common problems such as snoring and OSA.”

Snoring can affect the quality of sleep, increase risk of stroke, and
lead to obstructive sleep apnea syndrome (OSAS) where the airway is
physically obstructed for periods of time during sleep.

According to Lyle Hawkins, CEO of CrossCoat Medical LLC, “Virtually all
of the treatments offered in the market don’t cure the problem, they
only mask it. And, the surgical options are very painful. We’re on track
to offer a simple and virtually painless option for snoring/OSA.”

For additional information or to discuss investment opportunities,
contact Lyle Hawkins 502.419.8099 or LHawkins@CrossCoatMedical.com.

Contacts

CrossCoat Medical LLC
Lyle Hawkins, 502-419-8099
LHawkins@CrossCoatMedical.com